Market closed
Elevation Oncology/$ELEV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Ticker
$ELEV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
34
Website
ELEV Metrics
BasicAdvanced
$23M
-
-$0.78
1.38
-
Price and volume
Market cap
$23M
Beta
1.38
52-week high
$0.56
52-week low
$0.22
Average daily volume
1.9M
Financial strength
Current ratio
21.206
Quick ratio
20.861
Long term debt to equity
51.868
Total debt to equity
51.868
Interest coverage (TTM)
-11.18%
Management effectiveness
Return on assets (TTM)
-30.25%
Return on equity (TTM)
-77.48%
Valuation
Price to book
0.38
Price to tangible book (TTM)
0.38
Price to free cash flow (TTM)
-0.608
Growth
Earnings per share change (TTM)
-37.93%
3-year earnings per share growth (CAGR)
-33.50%
ELEV News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Elevation Oncology stock?
Elevation Oncology (ELEV) has a market cap of $23M as of April 19, 2025.
What is the P/E ratio for Elevation Oncology stock?
The price to earnings (P/E) ratio for Elevation Oncology (ELEV) stock is 0 as of April 19, 2025.
Does Elevation Oncology stock pay dividends?
No, Elevation Oncology (ELEV) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Elevation Oncology dividend payment date?
Elevation Oncology (ELEV) stock does not pay dividends to its shareholders.
What is the beta indicator for Elevation Oncology?
Elevation Oncology (ELEV) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.